CompletedPHASE2, PHASE3NCT01486927

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

Studying Hemophilia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
CSL Behring
Principal Investigator
Program Director
CSL Behring
Intervention
rVIII-SingleChain(biological)
Enrollment
175 enrolled
Eligibility
12-65 years · MALE
Timeline
20122014

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01486927 on ClinicalTrials.gov

Other trials for Hemophilia

Additional recruiting or active studies for the same condition.

See all trials for Hemophilia

← Back to all trials